signos eléctricos premonitorios; arritmias ventriculares malignas; terapia anticancerígena

Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB. Introducing a new entity: chemotheraphy-induced arrhythmia. Europace 2009;11:1579-86.

Antzelevitch, C. Cardiac repolarization. The long and short of it. Europace 2005;7:53-9.

Verrier RL, Huikuri H. Tracking interlead heterogeneity of R-and T-wave morphology to disclose latentrisk for sudden cardiac death. Heart Rhythm 2017;14(10):1466-75.

Kentta TV,Nearing BD, Porthan K, Tikkanen JT, Vitasalo M, Nieminen MS et al. Prediction of sudden cardiac death with automated high-throughput analysis of heterogeneity in standard resting 12-lead electrocardiograms. Heart Rhythm 2016;13:713-20.

Shimizu W. Where does heterogeneity exist in ventricular tachyarrhythmias? Heart Rhythm 2015;12:1304-5.

Coronel R, Wilms-Shopman FJG, Opthof T, Janse MJ. Dispersion of repolarization and arrhythmogenesis. Heart Rhythm 2009;6:537-43.

Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nantha Kumar K et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 2017. DOI:10.1161/JAHA.117.007724.

Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer treatment reviews 2018;63:135-43.

Buza V, Rajagopalau B, Curtis AB. Cancer treatment-induced arrhythmias focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol 2017 DOI:10.1161/CIRCEP.117.005443.

Dorantes M, Bazán M. Repolarización ventricular en la terapia oncológica. CorSalud 2019;11:146-52.

Dorantes M, Jerez Ana M. Arritmias y muerte súbita en la falla cardiaca: estratificación eléctrica de grupos de riesgo. CorSalud 2019;11:54-61.

Dorantes M. Signos eléctricos premonitorios de riesgo: cuál es el mejor. Controversia no terminada, en impetuoso crecimiento. CorSalud 2010;2:55-61.

Alemán A, Dorantes M, Castro J, González L,Coto Y, Rodríguez M. Arritmias ventriculares malignas en pacientes con cardiodesfibrilador implantable: signos eléctricos predictores de recidivas. CorSalud 2014;6:63-9.

Dorantes M. Despolarización y repolarización ventriculares para estratificar riesgo de arritmias ventriculares malignas y muerte súbita. CorSalud 2018;10:266-9.

Viskin S. The QT interval: too long, too short or just right. Heart Rhythm 2009;6(5):711-15.

Parvez B, Darbar D. Novel ECG markers for ventricular repolarization: is the QT interval obsolete? Heart Rhythm 2011. doi:10.1016/j.hrthm.2011.02.020

Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet 2008;372:750-63.

Laksman ZWM, Krahn AD. Fast and spurious: correcting the QT interval. Heart Rhythm 2016;13:536-7.

Khakpour H, Vaseghi M. Electrocardiographic Tpeak to Tend interval: the short and long of it. Heart Rhythm 2016;13:925-6.

Tse G, Gong M, Wong WT, Georgopoulos S, Letsas KP, Vassiliou VS et al. The Tpeak-Tend interval as an electrocardiographic risk marker of arrhythmic and mortality outcomes: a systematic review and meta-analysis. Heart Rhythm 2017;14:1131-7.

Virizuela JA, García AM, de las Peñas R, Santaballa A, Andres R, Beato C et al. SEOM clinical guidelines on cardiovascular toxicity. Clinical and translational oncology 2019;21:94-105.

Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015;38:129-52.

Herrmann J. From trends to transformation: where cardio-oncology is to make a difference. Eur Heart J 2019;40:3898-900.

Luscher TF. Cardio-oncology: low-grade inflammation as a common pathway of cancer and cardiovascular disease. Eur Heart J 2019;40:3871-4.

Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40:3889-97.